(Q35129044)

6 August 2017

1 reference

title

Immunomodulation of invasive fungal infections (English)

1 reference

invasive fungal infections

6 August 2017

main subject

1 reference

4

Stephen Chanock

1 reference

6 August 2017

1

Emmanuel Roilides

1 reference

6 August 2017

Paraskevi Panagopoulou

object named as

Paraskevi Panagopoulou

series ordinal

3

1 reference

ORCID Public Data File 2021

author name string

Caron A Lyman

series ordinal

2

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Infectious Disease Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

193-219

1 reference

Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Management of fever in patients with cancer and treatment-induced neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Therapy-induced alterations in host defense in children receiving therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Influence of host genetics on the severity of coccidioidomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Chronic granulomatous disease. Report on a national registry of 368 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Genetic, biochemical, and clinical features of chronic granulomatous disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Shattuck lecture--medical and societal consequences of the Human Genome Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Mining variations in genes of innate and phagocytic immunity: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Polygenic and multifactorial disease gene association in man: Lessons from AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Variation is the spice of life

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Role of hemopoietic growth factors and cytokines in host defense against fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Review: Nomenclature and Biologic Significance of Cytokines Involved in Inflammation and the Host Immune Response

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with Candida albicans: acceleration of recovery from neutropenia and potentiation of anti-C. albicans resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida, infections in normal and immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Modulation of Neutrophil‐Mediated Activity Against the Pseudohyphal Form ofCandida albicansby Granulocyte Colony‐Stimulating Factor (G‐CSF) Administered In Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Granulocyte Colony‐Stimulating Factor Administered In Vivo Augments Neutrophil‐Mediated Activity against Opportunistic Fungal Pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Response of human polymorphonuclear leukocytes and monocytes to Trichosporon beigelii: host defense against an emerging opportunistic pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

In vivo effects of macrophage colony-stimulating factor on human monocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Cytokines as therapy for opportunistic fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Gamma-interferon restores listericidal activity and concurrently enhances release of reactive oxygen metabolites in dexamethasone-treated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interferon- and Tumor Necrosis Factor- Protect Mice from Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Role of cytokines in pulmonary antimicrobial host defense

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Antifungal type 1 responses are upregulated in IL-10-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interleukin-4 and -10 exacerbate candidiasis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Consensus on the clinical use of myeloid growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Clinical use of hematopoietic growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of l

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind contro

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Granulocyte transfusions. Time for a second look

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

In vivo effects of recombinant human granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

The effect of granulocyte colony-stimulating factor administration in healthy donors before bone marrow harvesting

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Functional characteristics of neutrophils collected and stored after administration of G-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

The pathology of transfusion-related acute lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Immunotherapy in patients with systemic mycoses: a promising adjunct.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Combination immunotherapy and antifungal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Malignancy: Granulocyte Colony Stimulating Factor Increases the Efficacy of Conventional Amphotericin in the Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients following Intensive Chemotherapy or Bone Marrow Transplantation f

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Host Immune Reactivity Determines the Efficacy of Combination Immunotherapy and Antifungal Chemotherapy in Candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: response to GM-CSF therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Use of macrophage colony-stimulating factor in the treatment of fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Multifocal osteomyelitis caused byPaecilomyces varioti in a patient with chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Aspergillus osteomyelitis in chronic granulomatous disease: treatment with recombinant gamma-interferon and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-gamma and granulocyte-colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Multiple fungal brain abscess in a child with acute myeloblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Successful treatment of invasive thoracopulmonary mucormycosis in a patient with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Role of granulocyte colony-stimulating factor in the treatment of mucormycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900070-3

7 January 2021

10.1016/S0891-5520(02)00070-3

Identifiers

DOI

1 reference

6 August 2017

1 reference